Breaking News Instant updates and real-time market news.

AAPL

Apple

$161.50

2.87 (1.81%)

, ALXN

Alexion

$142.93

1.74 (1.23%)

09:29
09/12/17
09/12
09:29
09/12/17
09:29

On The Fly: Pre-market Movers

HIGHER: Apple (AAPL), up just under 1% ahead of the tech giant's launch event... Alexion Pharmaceuticals (ALXN), up 2.1% after announcing restructuring plan... DowDuPont (DWDP), up 1.3% after announcing results of comprehensive portfolio review and realigning into three intended companies. LOWER: Brookfield Infrastructure (BIP), down 5.6% after its 16.6M share Spot Secondary priced at $42.10... Nucor (NUE), down 1% after being downgraded to Equal Weight from Overweight at Morgan Stanley.

AAPL

Apple

$161.50

2.87 (1.81%)

ALXN

Alexion

$142.93

1.74 (1.23%)

DWDP

DowDuPont

BIP

Brookfield Infrastructure

NUE

Nucor

  • 12

    Sep

  • 12

    Sep

  • 12

    Sep

  • 27

    Sep

  • 23

    Oct

  • 12

    Sep

AAPL Apple
$161.50

2.87 (1.81%)

09/12/17
MSCO
09/12/17
NO CHANGE
MSCO
Augmented Reality the next 'killer app' to power Apple, says Morgan Stanley
A team of Morgan Stanley analysts including Katy Huberty, Brian Nowak and Grace Chen, among others, state in a new note to investors that they view Augmented Reality, or AR, as a revolutionary trend that can be "the next killer app" to extend the life of the smartphone market and accelerate device upgrades, led by Apple's (AAPL) iPhone. The analysts, who compare the impact of AR to the launch of Apple's App Store nearly a decade ago, add that they "don't expect the Android ecosystem to stand still in response." Huberty and the team raised the firm's "bull case" valuation of Apple, which they see taking the lead in AR, to $253 from $203. While they see Apple as "the clear leader" in AR, Google (GOOG) and Tencent (TCEHY) are also well-positioned and "interesting use cases" in e-commerce could benefit Alibaba (BABA) and Amazon (AMZN), they add.
09/12/17
UBSW
09/12/17
NO CHANGE
Target $180
UBSW
Buy
Apple shares should outperform over next 6-12 months, says UBS
UBS analyst Steven Milunovich said Apple's stock performance from the last five product announcements has been pretty consistent, with the stock historically being down in the two weeks preceding the event, up or down 1%-2% the day of the event, up between the event and the launch, and up heading into earnings. He thinks there is somewhat greater near-term downside risk this time, but expects the stock to outperform over the next 6-12 months. Milunovich reiterated his Buy rating and $180 price target on Apple shares.
09/12/17
JPMS
09/12/17
NO CHANGE
Target $315
JPMS
Overweight
JPMorgan still confident Apple will integrate Broadcom's wireless charging
Ahead of today's next generation iPhone announcement, JPMorgan analyst Harlan Sur says he remains confident that Apple (AAPL) will integrate Broadcom's (AGO) wireless charging chip into the next iPhone family in the second half of 2017. Broadcom commenced manufacturing production of the chip back in late June with its foundry partners, Sur tells investors in a research note. The analyst is also confident that Apple will also use Broadcom's next generation Wi-Fi/Bluetooth combo chip which enables simultaneous Wi-Fi data transmit/receive on both 2.4Ghz/5Ghz bands and the new Bluetooth 5.0 standard. He sees at least a $3-$4 step-up, or 40%-45% increase, in dollar content for Broadcom in the new iPhone relative to last year's models. Sur reiterates an Overweight rating on Broadcom with a $315 price target.
09/12/17
JPMS
09/12/17
NO CHANGE
JPMS
JPMorgan lays out iPhone content winners and losers into launch event
JPMorgan analyst Harlan Sur believes Apple's (AAPL) launch event today will be positive for Broadcom (AVGO) and Qorvo (QRVO) as well as Micron (MU) and Intel (INTC). The analyst sees content gains by Broadcom in wireless charging, touch controller, Wi-Fi/Bluetooth and GPS connectivity, and by Qorvo in low band power amplifier duplexers share and antenna tuning. Other companies with significant Apple exposure that would benefit from increased unit sales and/or modest content gains include Intel, Skyworks (SWKS), Knowles (KN), Micron, Cypress Semiconductor (CY), NXP Semiconductors (NXPI) and Texas Instruments (TXN), Sur tells investors in a research note. The analyst sees Analog Devices' (ADI) blended content at Apple declining as he believes the company will not be the touch controller for the OLED-version of the iPhone.
ALXN Alexion
$142.93

1.74 (1.23%)

07/28/17
LEER
07/28/17
NO CHANGE
Target $170
LEER
Outperform
Alexion price target raised to $170 from $136 at Leerink
Leerink analyst Geoffrey Porges raised his forecasts for Alexion's revenue and earnings, noting that his estimates are now above recent consensus for 2018-2020, citing his belief that the company's core Soliris franchise is "more or less intact" and management can deliver on its positive margin guidance. He raised his price target on Alexion shares to $170 from $136 and keeps an Outperform rating on the stock.
09/07/17
LEER
09/07/17
NO CHANGE
LEER
Alexion, Celgene top picks at Leerink
Leerink analyst Geoffrey Porges notes large cap biotech stocks have performed strongly this year and have reversed some of the wide discount they were carrying compared to their history and to other medical products sectors. Further, he points out consensus revenue and earnings estimates for biotech companies have started to trend positively, after negative revisions earlier in the year. Porges still sees significant upside for many of the names in his coverage, and he anticipates that further appreciation can occur on the basis of recovering sentiment and multiples, further estimate revisions toward his current models, and confirmation of option value for unpriced pipeline opportunities. The analyst top picks are now Alexion (ALXN), Celgene (CELG), Regeneron (REGN), and Vertex (VRTX). Among his Market Perform rated stocks, his preference would be for AbbVie (ABBV).
09/05/17
JPMS
09/05/17
UPGRADE
Target $175
JPMS
Overweight
Alexion upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Alexion Pharmaceuticals to Overweight and raised his price target for the shares to $175 from $163. The stock closed Friday up $1.67 to $144.08. Alexion set low expectations for second half of 2017 earnings and the Street is now shifting its focus to clinical catalysts over the next 6-12 months, Rama tells investors in a research note. The analyst has a positive stance on a supplemental approval of Soliris for myasthenia gravis by the October FDA action date as well as continued confidence in ALXN1210 as a "long-term defense point for Alexion's complement franchise."
08/16/17
EVER
08/16/17
INITIATION
Target $137
EVER
In Line
Alexion initiated with an In Line at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Alexion with an In Line and a $137 price target.
DWDP DowDuPont

09/11/17
BOFA
09/11/17
INITIATION
Target $78
BOFA
Buy
DowDuPont initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Steve Byrne initiated DowDuPont with a Buy and a $78 price target.
09/11/17
09/11/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: DowDuPont (DWDP) initiated with a Buy at BofA/Merrill and an Underweight at Barclays. 2. Brookfield Infrastructure (BIP) initiated with an Outperform at BMO Capital. 3. Micron (MU) initiated with an Outperform at FBN Securities. 4. TechnipFMC (FTI) initiated with a Hold at HSBC. 5. Thor Industries (THO) initiated with a Hold at Aegis. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/12/17
BOFA
09/12/17
NO CHANGE
Target $78
BOFA
Buy
DowDuPont added to the US 1 List at BofA/Merrill
BofA/Merrill analyst Steve Byrne added DowDuPont to the US 1 List due to substantial EBITDA growth from synergies and growth initiatives. The analyst sees several catalysts ahead from the release of pro-forma financials in November, clarity on the dividend policy, near-term synergy realization, and the McKinney board review of the spincos. Byrne rates DowDuPont a Buy with a $78 price target.
09/12/17
LEHM
09/12/17
INITIATION
Target $67
LEHM
Underweight
DowDuPont initiated with an Underweight at Barclays
Barclays analyst Duffy Fischer started DowDuPont with an Underweight rating and $67 price target. The analyst says the Street is placing a higher probability of positive outcomes than he is regarding management direction, the spin company structure, the impact of synergies on the bottom line and the Agriculture business.
BIP Brookfield Infrastructure

08/22/17
08/22/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Mylan (MYL) downgraded to Hold from Buy at Argus with analyst Jasper Hellweg citing the cut in 2017 guidance. He said Mylan may also have difficulty improving operations in the near-term due to unfavorable EpiPen regulatory developments, pricing pressures, and increased competition. 2. Brookfield (BIP) downgraded to Neutral from Outperform at Credit Suisse, with analyst Andrew Kuske saying he is exiting his long "tactical trade" given recent outperformance. 3. Global Medical REIT (GMRE) downgraded to Neutral from Buy at DA Davidson with analyst Barry Oxford saying that the stock "could be range bound for a period of time" following the departures of the REIT's CEO and CFO and due to "potential concerns regarding the dividend and acquisitions." 4. NxStage Medical (NXTM) downgraded to Market Perform from Outperform at Leerink, as analyst Danielle Antalffy said it is unlikely another bidder will top Fresenius Medical's (FMS) $30 per share offer for the company. 5. Hikma (HKMPY) downgraded to Neutral from Buy at Goldman Sachs, with analyst Yulia Gerasimova citing Roxane integration issues, delayed generic Advair approval, ongoing U.S. generics pricing erosion, and multiple guidance downgrades from the company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/22/17
FBCO
08/22/17
DOWNGRADE
FBCO
Neutral
Brookfield downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Andrew Kuske downgraded Brookfield Infrastructure to Neutral saying he is exiting his long "tactical trade" given recent outperformance and maintained a $44 price target on shares.
09/11/17
BMOC
09/11/17
INITIATION
BMOC
Outperform
Brookfield Infrastructure initiated with an Outperform at BMO Capital
BMO Capital analyst Devin Dodge started coverage of Brookfield Infrastructure with a $48 price target and an Outperform rating. The analyst expects the REIT's FFO and unit growth to increase at a compound annual growth rate of 15% through 2019, driven by what he sees as its "strong backlog of organic growth opportunities.". The analyst thinks that Brookfield could beat his estimates driven by favorable M&A and additional projects. He estimates that its distribution will grow at a CAGR of 11% through 2019, surpassing its targeted range.
NUE Nucor

08/17/17
08/17/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Illinois Tool Works (ITW) downgraded to Underweight from Neutral at JPMorgan with analyst Ann Duignan citing valuation and expectations for continued multiple compression on weaker than peer organic growth. The analyst lowered her price target for the shares to $132 from $141. 2. Boston Properties (BXP) downgraded to Outperform from Top Pick at RBC Capital with analyst Michael Carroll saying he thinks that upcoming move-outs by the REIT's tenants, along with slower than expected macro economic growth, will negatively impact its growth. 3. Sanderson Farms (SAFM) downgraded to Equal Weight from Overweight at Stephens with analyst Farha Asiam citing valuation. 4. Nucor (NUE) downgraded to Sector Weight from Overweight at KeyBanc with analyst Philip Gibbs citing spread and volume pressures. 5. Netshoes (NETS) downgraded to Hold from Buy at Jefferies with analyst Brian Fitzgerald citing continuing softness in the consumption environment in Brazil as well as limited visibility into near-term operating results. The analyst lowered his price target for the shares to $18.50 from $22. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/06/17
MACQ
09/06/17
INITIATION
Target $57
MACQ
Neutral
Nucor initiated with a Neutral at Macquarie
Macquarie analyst David Lipschitz initiated Nucor with a Neutral and a $57 price target. The analyst's 2017 and 2018 estimates of $4.11 and $4.15, respectively, are below consensus of $4.15 and $4.59 as he believes the current cycle will develop into a steady but decelerating domestic demand story.
09/12/17
MSCO
09/12/17
DOWNGRADE
MSCO
Equal Weight
Nucor downgraded to Equal Weight from Overweight at Morgan Stanley
09/12/17
09/12/17
DOWNGRADE

Equal Weight
Nucor, Steel Dynamics downgraded on margin concerns at Morgan Stanley
As previously reported, Morgan Stanley analyst Piyush Sood downgraded Nucor (NUE) and Steel Dynamics (STLD), each to Equal Weight from Overweight, contending that the crosscurrents of higher U.S. steel and scrap pricing and weaker non-residential and auto demand are a drag on these "mini mills" and peer Commercial Metals (CMC). However, the net impact of the pricing and demand factors is beneficial to U.S. Steel (X), added Sood, who keeps an Overweight rating on that stock.

TODAY'S FREE FLY STORIES

JOE

Saint Joe Co.

$18.60

0.45 (2.48%)

16:46
09/22/17
09/22
16:46
09/22/17
16:46
Hot Stocks
Breaking Hot Stocks news story on Saint Joe Co. »

Fairholme raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:40
09/22/17
09/22
16:40
09/22/17
16:40
General news
Moody's downgrades UK's rating to Aa2, changes outlook to stable »

Moody's Investors…

A

Agilent

$65.78

-0.14 (-0.21%)

, MRK

Merck

$65.13

-0.47 (-0.72%)

16:36
09/22/17
09/22
16:36
09/22/17
16:36
Hot Stocks
Agilent receives expanded FDA approval for the use of Dako PD-L1 IHC 22C3 »

Agilent Technologies…

A

Agilent

$65.78

-0.14 (-0.21%)

MRK

Merck

$65.13

-0.47 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Sep

  • 08

    Nov

  • 30

    Nov

TYHT

Shineco

$3.23

-0.45 (-12.23%)

16:35
09/22/17
09/22
16:35
09/22/17
16:35
Hot Stocks
Shineco enters into strategic cooperation to establish Apocynum Industrial Park »

Shineco announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCI

Appliance Recycling

$1.16

0.03 (2.65%)

16:34
09/22/17
09/22
16:34
09/22/17
16:34
Hot Stocks
Appliance Recycling gets written notice of default »

On September 20,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNVA

Rennova Health

$0.22

0.0086 (4.07%)

16:31
09/22/17
09/22
16:31
09/22/17
16:31
Hot Stocks
Rennova Health announces 1 for 15 reverse stock split »

Rennova Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCI

Appliance Recycling

$1.16

0.03 (2.65%)

16:31
09/22/17
09/22
16:31
09/22/17
16:31
Hot Stocks
Breaking Hot Stocks news story on Appliance Recycling »

Appliance Recycling gets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
09/22/17
09/22
16:30
09/22/17
16:30
Options
Preliminary option volume of 13.9M today »

Preliminary option volume…

EKSO

Ekso Bionics

$1.28

0.14 (12.28%)

16:23
09/22/17
09/22
16:23
09/22/17
16:23
Hot Stocks
Ekso Bionics awarded government contract »

The Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

, AET

Aetna

$153.57

0.18 (0.12%)

16:22
09/22/17
09/22
16:22
09/22/17
16:22
General news
On The Fly: Top stock stories for Friday »

The major averages…

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CI

Cigna

$182.74

0.61 (0.33%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

FSLR

First Solar

$51.41

2.65 (5.43%)

FINL

Finish Line

$9.73

0.51 (5.53%)

ASND

Ascendis Pharma

$34.24

6.5 (23.43%)

VSAR

Versartis

$2.68

-18.925 (-87.62%)

ICPT

Intercept

$61.59

-12.11 (-16.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Oct

DLR

Digital Realty

$114.51

-1.72 (-1.48%)

16:19
09/22/17
09/22
16:19
09/22/17
16:19
Syndicate
Breaking Syndicate news story on Digital Realty »

Digital Realty files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

16:17
09/22/17
09/22
16:17
09/22/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSS

TSYS

$69.09

0.28 (0.41%)

16:16
09/22/17
09/22
16:16
09/22/17
16:16
Hot Stocks
TSYS announces resignation of COO Pamela Joseph »

TSYS announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

16:16
09/22/17
09/22
16:16
09/22/17
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$170.54

-0.57 (-0.33%)

16:15
09/22/17
09/22
16:15
09/22/17
16:15
Hot Stocks
Facebook's Zuckerberg plans to sell up to 75M shares to fund charity initiatives »

On September 22 Mr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

IDA

IDACORP

$87.79

-0.73 (-0.82%)

16:13
09/22/17
09/22
16:13
09/22/17
16:13
Hot Stocks
IDACORP raises quarterly dividend 7.3% to 59c per share »

The dividend declaration,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRX

Valeritas

$3.06

-0.23 (-6.99%)

16:13
09/22/17
09/22
16:13
09/22/17
16:13
Syndicate
Valeritas announces common stock purchase agreement by Aspire Capital »

Valeritas Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$170.54

-0.57 (-0.33%)

16:12
09/22/17
09/22
16:12
09/22/17
16:12
Hot Stocks
Facebook dumps plan for new class of shares »

On September 21 the board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

DCIX

Diana Containerships

$0.42

-0.0373 (-8.16%)

16:11
09/22/17
09/22
16:11
09/22/17
16:11
Hot Stocks
Diana Containerships announces one-for-three reverse stock split »

Diana Containerships…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEP

Spectra Energy Partners

$43.89

0.34 (0.78%)

16:10
09/22/17
09/22
16:10
09/22/17
16:10
Syndicate
Breaking Syndicate news story on Spectra Energy Partners »

Spectra Energy Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEV

Sevcon

$22.04

0.04 (0.18%)

, BWA

BorgWarner

$50.00

0.41 (0.83%)

16:10
09/22/17
09/22
16:10
09/22/17
16:10
Hot Stocks
Sevcon stockholders approve acquisition by BorgWarner »

Sevcon (SEV) announced…

SEV

Sevcon

$22.04

0.04 (0.18%)

BWA

BorgWarner

$50.00

0.41 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Oct

ATOS

Atossa Genetics

$0.49

-0.0296 (-5.71%)

16:07
09/22/17
09/22
16:07
09/22/17
16:07
Syndicate
Breaking Syndicate news story on Atossa Genetics  »

Atossa Genetics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CB

Chubb

$142.68

-0.27 (-0.19%)

16:06
09/22/17
09/22
16:06
09/22/17
16:06
Hot Stocks
Chubb CEO issues statement on EU-U.S. covered agreement »

Evan Greenberg, Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 31

    Jan

AAPL

Apple

$153.39

-2.68 (-1.72%)

15:40
09/22/17
09/22
15:40
09/22/17
15:40
Options
Active trading in Apple as iPhone 8 makes a debut »

Active trading in Apple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

MRK

Merck

15:39
09/22/17
09/22
15:39
09/22/17
15:39
Hot Stocks
Merck gets FDA approval for Keytruda »

Merck announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Sep

  • 08

    Nov

  • 30

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.